Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.6%

3 terminated out of 22 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results79% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (10)
P 1 (2)
P 2 (3)

Trial Status

Completed11
Unknown4
Terminated3
Recruiting2
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT00326482Completed

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT07476703Recruiting

Expanded Studies on the SCAPIS Stockholm Reexamination Cohort

NCT07254533Not ApplicableNot Yet Recruiting

Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy

NCT05640947Not ApplicableRecruiting

Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass

NCT07052682Phase 1TerminatedPrimary

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT05864391Phase 1TerminatedPrimary

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

NCT00886301Not ApplicableCompletedPrimary

Fatty Liver and Ectopic Fat in Overweight and Obese Patients

NCT04063826Not ApplicableUnknownPrimary

PET-MR Study of Fatty Liver

NCT03915002Completed

Integrated Approaches for Identifying Molecular Targets in Liver Disease

NCT05946330Not ApplicableUnknown

Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).

NCT02378259Not ApplicableActive Not Recruiting

Randomized Clinical Trial; Medical vs Bariatric Surgery for Adolescents (13-16 y) With Severe Obesity

NCT01523639Phase 2Terminated

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

NCT01556113Not ApplicableCompleted

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

NCT01645852Not ApplicableCompleted

A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection

NCT00575757CompletedPrimary

Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV

NCT01154985Phase 2CompletedPrimary

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

NCT01246388Unknown

Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy

NCT02009592Not ApplicableCompleted

Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients

NCT01147523Phase 2Completed

Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease

NCT01476995Completed

Prognostic Indicators as Provided by the EPIC ClearView

Scroll to load more

Research Network

Activity Timeline